Biomedicines (Mar 2024)

Role of Breast Cancer Risk Estimation Models to Identify Women Eligible for Genetic Testing and Risk-Reducing Surgery

  • Azzurra Irelli,
  • Leonardo Valerio Patruno,
  • Sofia Chiatamone Ranieri,
  • Daniela Di Giacomo,
  • Sara Malatesta,
  • Edoardo Alesse,
  • Alessandra Tessitore,
  • Katia Cannita

DOI
https://doi.org/10.3390/biomedicines12040714
Journal volume & issue
Vol. 12, no. 4
p. 714

Abstract

Read online

Hereditary breast and ovarian cancer (HBOC) syndrome is responsible for approximately 10% of breast cancers (BCs). The HBOC gene panel includes both high-risk genes, i.e., a four times higher risk of BC (BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11 and TP53), and moderate-risk genes, i.e., a two to four times higher risk of BC (BARD1, CHEK2, RAD51C, RAD51D and ATM). Pathogenic germline variants (PGVs) in HBOC genes confer an absolute risk of BC that changes according to the gene considered. We illustrate and compare different BC risk estimation models, also describing their limitations. These models allow us to identify women eligible for genetic testing and possibly to offer surgical strategies for primary prevention, i.e., risk-reducing mastectomies and salpingo-oophorectomies.

Keywords